Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

Cortés, J, Rugo, HS, Twelves, C et al. (10 more authors) (2016) Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. SpringerPlus, 5 (1). 1033. ISSN 2193-1801

Abstract

Metadata

Authors/Creators:
  • Cortés, J
  • Rugo, HS
  • Twelves, C
  • Awada, A
  • Perez, EA
  • Im, SA
  • Zhao, C
  • Hoch, U
  • Tomkinson, D
  • Buchanan, J
  • Tagliaferri, M
  • Hannah, A
  • O'Shaughnessy, J
Copyright, Publisher and Additional Information: © 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Etirinotecan pegol; Metastatic breast cancer; Chemotherapy safety; Chemotherapy side effects
Dates:
  • Published: 1 December 2016
  • Accepted: 27 May 2016
  • Published (online): 8 July 2016
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 02 Dec 2016 16:18
Last Modified: 05 Oct 2017 16:26
Published Version: http://doi.org/10.1186/s40064-016-2446-4
Status: Published
Publisher: SpringerOpen
Identification Number: https://doi.org/10.1186/s40064-016-2446-4

Share / Export

Statistics